Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Off-label testosterone therapy is associated with higher long-term cardiovascular risk in men.

EBioMedicine·2026
Same author

Psychiatric Risk in Chronic Spontaneous Urticaria: A Retrospective Cohort Study.

Acta dermato-venereologica·2026
Same author

Pyoderma gangrenosum is associated with excess incident major atherothrombotic events.

Atherosclerosis·2026
Same author

Second-Generation H1-Antihistamines Do Not Alter Dementia Risk in Type 2 Inflammatory Diseases: A Target Trial Emulation Using Real-World Data.

The journal of allergy and clinical immunology. In practice·2026
Same author

ANCA-associated vasculitis is associated with an increased risk of cardiac and vascular morbidity: results of a large-scale propensity-matched global retrospective cohort study.

Frontiers in immunology·2026
Same author

Elevated lymphoma risk in patients with chronic pruritus and chronic prurigo.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026

Related Experiment Video

Updated: Feb 25, 2026

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model
11:38

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model

Published on: July 2, 2016

11.0K

Reconstructing the immune system with lentiviral vectors.

Henning Olbrich1,2,3, Constanze Slabik1,2,3, Renata Stripecke4,5,6

  • 1German Center for Infection Research, Partner Site Hannover, Hannover, Germany.

Virus Genes
|July 27, 2017
PubMed
Summary

Lentiviral vectors (LVs) show promise for improving human immunity, offering advantages over other viral systems. Their robust transduction efficiency enables diverse immune therapeutic applications, including cancer and infectious disease treatments.

Keywords:
CAR-T cellsCancerCellsChronic infectionsDendriticHematopoietic stem cellsLentiviral vectorsT cellsTCR

More Related Videos

Production of Lentiviral Vectors for Transducing Cells from the Central Nervous System
08:46

Production of Lentiviral Vectors for Transducing Cells from the Central Nervous System

Published on: May 24, 2012

37.1K
Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models
08:14

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Published on: October 3, 2019

13.1K

Related Experiment Videos

Last Updated: Feb 25, 2026

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model
11:38

Stem-cell Based Engineered Immunity Against HIV Infection in the Humanized Mouse Model

Published on: July 2, 2016

11.0K
Production of Lentiviral Vectors for Transducing Cells from the Central Nervous System
08:46

Production of Lentiviral Vectors for Transducing Cells from the Central Nervous System

Published on: May 24, 2012

37.1K
Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models
08:14

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Published on: October 3, 2019

13.1K

Area of Science:

  • * Gene therapy and immunology
  • * Viral vector development
  • * Cellular immunotherapy

Background:

  • * Lentiviral vectors (LVs) have advanced from research to clinical trials with strong safety and efficacy.
  • * LVs offer significant advantages over other viral vector systems for enhancing human immunity.
  • * Robust and persistent transduction of blood cells by LVs supports broad immune therapeutic applications.

Purpose of the Study:

  • * To review the development and clinical applications of lentiviral vectors for immune enhancement.
  • * To discuss technological adaptations for ex vivo cell manipulation in lentiviral therapies.
  • * To explore the potential of in vivo lentiviral administration for future immune therapies.

Main Methods:

  • * Review of lentiviral vector applications in pre-clinical and clinical research.
  • * Discussion of ex vivo cell engineering techniques for immune cell therapies.
  • * Analysis of strategies for in vivo lentiviral vector targeting.

Main Results:

  • * Lentiviral vectors demonstrate remarkable safety and efficacy in clinical trials.
  • * Engineered T cells (CARs, TCRs) and dendritic cells show promise for cancer and chronic infection therapies.
  • * Lentiviral vectors enable targeting of various immune cells, including stem cells, lymphoid, and myeloid cells.

Conclusions:

  • * Lentiviral vectors are a powerful tool for developing advanced immune therapies.
  • * Ex vivo cell manipulation technologies are crucial for current lentiviral-based treatments.
  • * In vivo lentiviral vector administration is a key future direction for off-the-shelf immune therapies.